Article
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Cancer - 1 Jun 2020
Pal Sumanta K, Bajorin Dean, Dizman Nazli, Hoffman-Censits Jean, Quinn David I, Petrylak Daniel P, Galsky Matthew D, Vaishampayan Ulka, De Giorgi Ugo, Gupta Sumati, Burris Howard A, Soifer Harris S, Li Gary, Wang Hao, Dambkowski Carl L, Moran Susan, Daneshmand Siamak, Rosenberg Jonathan E
Abstract excerpt
BACKGROUND: Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1-3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB), the authors examined whether infigratinib had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.